HLS Therapeutics (HLS) Stock Overview
A specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
HLS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
HLS Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$4.39 |
| 52 Week High | CA$5.77 |
| 52 Week Low | CA$3.93 |
| Beta | 0.81 |
| 1 Month Change | 0.69% |
| 3 Month Change | -7.77% |
| 1 Year Change | 7.07% |
| 3 Year Change | -28.03% |
| 5 Year Change | -76.78% |
| Change since IPO | -62.12% |
Recent News & Updates
Recent updates
HLS Therapeutics Inc. (TSE:HLS) Just Reported, And Analysts Assigned A CA$6.80 Price Target
Nov 16
Vascepa Sales In Canada And Cost Cuts Will Transform Prospects
Significant revenue growth is expected from Vascepa in Canada, driven by increased prescriptions and stabilizing payer mix, positively impacting revenue.Are Investors Undervaluing HLS Therapeutics Inc. (TSE:HLS) By 45%?
Oct 26Pinning Down HLS Therapeutics Inc.'s (TSE:HLS) P/S Is Difficult Right Now
Sep 28Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results
May 12After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
Apr 14Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 06Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Nov 16Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Sep 13Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
May 05HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Apr 05HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
Mar 20HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of $0.05
Nov 30Downgrade: Here's How Analysts See HLS Therapeutics Inc. (TSE:HLS) Performing In The Near Term
Nov 11We Think HLS Therapeutics (TSE:HLS) Has A Fair Chunk Of Debt
Sep 14Shareholder Returns
| HLS | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0.5% | 18.0% | 3.7% |
| 1Y | 7.1% | 58.1% | 44.2% |
Return vs Industry: HLS underperformed the Canadian Pharmaceuticals industry which returned 58.1% over the past year.
Return vs Market: HLS underperformed the Canadian Market which returned 44.2% over the past year.
Price Volatility
| HLS volatility | |
|---|---|
| HLS Average Weekly Movement | 2.2% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 10.9% |
| 10% most volatile stocks in CA Market | 19.3% |
| 10% least volatile stocks in CA Market | 3.8% |
Stable Share Price: HLS has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: HLS's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 85 | Craig Millian | www.hlstherapeutics.com |
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels.
HLS Therapeutics Inc. Fundamentals Summary
| HLS fundamental statistics | |
|---|---|
| Market cap | CA$137.29m |
| Earnings (TTM) | -CA$17.27m |
| Revenue (TTM) | CA$77.12m |
Is HLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLS income statement (TTM) | |
|---|---|
| Revenue | US$55.50m |
| Cost of Revenue | US$15.79m |
| Gross Profit | US$39.71m |
| Other Expenses | US$52.14m |
| Earnings | -US$12.43m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 71.55% |
| Net Profit Margin | -22.40% |
| Debt/Equity Ratio | 79.1% |
How did HLS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/07 23:00 |
| End of Day Share Price | 2026/04/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HLS Therapeutics Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Michael Freeman | Raymond James Ltd. |